Business ❯Healthcare
Vaccine Development Sales Performance Covid-19 COVID-19 vaccines
The company surpassed analyst expectations, reaffirmed 2025 guidance, and outlined strategies to mitigate tariff impacts while navigating mixed portfolio performance.